Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
The study used natural language processing for computer-assisted review of electronic health records.
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Allogeneic CAR T-cells had “encouraging safety and efficacy” in patients with CD7-positive hematologic malignancies.
Axicabtagene ciloleucel led to higher response rates and higher toxicity rates than tisagenlecleucel in R/R DLBCL.
Allogeneic off-the-shelf CAR T-cells “showed evidence of antileukemic activity” in heavily pretreated patients...
Certain genetic features in tumor and plasma samples from patients with LBCL are associated with poor CD19-directed CAR-T...
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
CD19-directed CAR T-cells led to a complete remission in around half of patients with relapsed/refractory CNS lymphoma.
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Researchers have recently identified bacterial proliferation on the skin as a factor associated with the development of...
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Dr. Lentzsch and Dr. Wong discuss the role of transplantation in newly diagnosed systemic light chain (AL) amyloidosis...
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43%
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Researchers had not previously studied the long-term impact of omidubicel...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
The combination led to an overall survival rate of nearly 75% in patients with BPDCN...
First-line treatment with tagraxofusp led to an overall response rate of 75% in patients with blastic plasmacytoid...
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
A second allogeneic HSCT is a reasonable treatment option for patients with relapsed AML.
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Advances have been accomplished in the management of adults with acute lymphoblastic leukemia...
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
This article discusses managing the most difficult cases of CLL.
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Researchers have demonstrated the clinical importance of COVID-19 vaccination after anti-CD19 chimeric antigen receptor (CAR) ...
Transplant was associated with a lower incidence of disease relapse but did increase the mortality related to treatment.
Nearly a third of patients with chronic graft-versus-host disease (GVHD) were able to discontinue long-term systemic therapy ...
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Patients with newly diagnosed primary central nervous system lymphoma who received high-dose chemotherapy and autologous ...
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Cellenkos, Inc. to ...
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Results from the global, phase III TRANSFORM study support liso-cel as a new second-line treatment recommendation in patients ...
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
The overall efficacy of tisagenlecleucel was similar between the two groups. Flu/Cy led to more profound lymphocytopenia ...
This article discusses optimizing transplant-related care for patients with high-risk acute lymphoblastic...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Clinicians who specialize in BPDCN discuss the disease and novel therapeutic approaches to treating patients with BPCDN.
There was a global increase of 6.2% in autologous HSCT and 7.0% in allogeneic HSCT.
Researchers retrospectively analyzed 580 patients with AML receiving HSCT between January 1999 and November 2020.
Median PFS and OS were 25.8 months (95% CI, 9.6-47.6) and 46.6 months (95% CI, 24.9-not estimable), respectively.
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
CAR T-cell dysfunction marked by TIGIT expression may be driving poor response to therapy in patients with non-Hodgkin ...
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Black and Hispanic patients who underwent CAR T-cell therapy had outcomes comparable to their White and Asian counterparts.
A study of seven clinical trials around CAR T-cell therapies showed a substantially low enrollment of participants who were ...
University of Pennsylvania researchers have shortened the cell manufacturing process for CAR T-cell therapy, which is ...
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
Director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence Richard Pazdur, MD, has ...
On Feb. 15, Robert Califf, MD, was confirmed to lead the FDA as commissioner for the second time.
While the field of telehealth grew rapidly in the United States during the COVID-19 pandemic, many patients lack access to ...
In January, a private equity firm announced that it would buy MarketScan, a group of databases containing sensitive patient ...
The Government Accountability Office says the US Department of Health and Human Services is at high risk of mismanaging a ...
The FDA has approved an update to the prescribing information for all approved indications of axi-cel.
On average, pharmaceutical companies raised US list prices on cancer, diabetes, and other prescription drugs by 6.6% in the ...
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Abatacept has been U.S. Food and Drug Administraion (FDA)-approved as acute graft-versus-host disease (aGVHD) prophylaxis for ...
Life expectancy has improved since 1974 but remains 20.8% lower compared with the general population.
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
According to data from the ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) ...
Black patients with multiple myeloma (MM) who receive upfront hematopoietic autologous cell transplantation (ASCT) have ...
A study found that for people with MCL, patient demographics were associated with likelihood of receiving ASHCT.
A study found that Black Americans are underrepresented in clinical trials supporting approval of oral chemotherapy drugs ...
A study published in Bone Marrow Transplantation evaluated whether patient characteristics impacted the timeline to return to ...
Experts focus on the latest news and clinical development and impact for multiple myeloma.
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells (HSPC) mobilization, ...
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
A study did not observe racial disparities in the use of autologous hematopoietic cell transplantation (HCT) consolidative ...
Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple ...
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
Infection is a major driver of intensive care unit (ICU) admissions after hematopoietic cell transplantation (HCT), according ...
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
An analysis of patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplant (AHCT) showed that ...
The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Nina Shah, MD, talks about two multiple myeloma agents granted priority review by the FDA and data on these therapeutics.
A study published in the Journal of Clinical Oncology found that ixazomib maintenance therapy extended survival in patients ...
Ankit Kansagra, MD, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma.
Patients with CMML who received an allogeneic HSCT earlier in the course of their disease had better outcomes.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
